Related Experiment Video

Updated: Oct 16, 2025

Experimental Infection of Mice with the Parasitic Nematode Strongyloides ratti ratti Infection
10:12

Experimental Infection of Mice with the Parasitic Nematode Strongyloides ratti ratti Infection

Published on: January 17, 2025

672

Ivermectin treatment for Strongyloides infection in patients with COVID-19

Ontario Covid-, Science Advisory Table,

    Canada Communicable Disease Report = Releve Des Maladies Transmissibles Au Canada
    |October 20, 2021
    PubMed

    Insights

    Ivermectin is not recommended for COVID-19 treatment. However, some COVID-19 patients on immunomodulatory therapies may need ivermectin to prevent severe Strongyloides infection.

    Area of Science:

    • Infectious Diseases
    • Pharmacology

    Background:

    • Ivermectin is an antiparasitic drug.
    • Coronavirus disease 2019 (COVID-19) is a global health concern.
    • The use of ivermectin for COVID-19 is controversial and not recommended by health authorities.

    Purpose of the Study:

    • To clarify the role of ivermectin in the context of COVID-19.
    • To highlight the risks associated with ivermectin use in COVID-19 patients.
    • To emphasize the importance of screening for Strongyloides stercoralis in certain COVID-19 patients.

    Main Methods:

    • Review of current medical literature and guidelines.
    • Analysis of potential drug interactions and side effects.
    • Identification of patient populations at risk for specific complications.

    Main Results:

    • Ivermectin is not recommended for prophylaxis or treatment of COVID-19.
    • Inappropriate ivermectin use can lead to drug shortages for parasitic infections.
    • COVID-19 patients receiving immunomodulatory therapies are at risk for Strongyloides hyperinfection syndrome.

    Conclusions:

    • Clinicians should not use ivermectin for COVID-19.
    • Screening for Strongyloides stercoralis is crucial in COVID-19 patients considered for immunomodulatory therapies.
    • Early detection and treatment of Strongyloides prevent potentially fatal hyperinfection syndrome.
    Keywords:
    COVID-19IL-6 inhibitorsStrongyloidescorticosteroidsimmunosuppressionivermectinstrongyloidiasis

    More Related Videos

    Generating Transgenics and Knockouts in Strongyloides Species by Microinjection09:42

    Generating Transgenics and Knockouts in Strongyloides Species by Microinjection

    Published on: October 7, 2021

    2.9K
    Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians06:49

    Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

    Published on: March 14, 2014

    11.8K

    Related Concept Videos

    Drugs for Treatment of Ulcerative Colitis in IBD01:29

    Drugs for Treatment of Ulcerative Colitis in IBD

    Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
    268
    Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

    Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

    Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
    624
    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

    Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
    286
    Myocarditis III: Medical Management01:14

    Myocarditis III: Medical Management

    Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
    31
    Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

    Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

    Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
    238
    Pneumonia IV: Management01:28

    Pneumonia IV: Management

    The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
    Bacterial Pneumonia Treatment
    For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
    499